ISRCTN68222771已完成未知
Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period.A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus paroxetine (20 to 30 mg/day).Twelve-week treatment plus optional continuation for 12 weeks.
Institut de Recherches Internationales Servier (France)0 个研究点目标入组 400 人开始时间: 2006年3月31日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 400
研究概览
简要总结
2013 results in: https://www.ncbi.nlm.nih.gov/pubmed/23023074
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Out-patients aged at least 60 years with recurrent major depressive episode according to diagnostic and statistical manual of mental disorders (DSM) IV
排除标准
- •1. Patients treated with electroconvulsive therapy (ECT) within the last three months
- •2. Insight-oriented and structured psychotherapy started within the three months before inclusion
- •3. Light-therapy started within two weeks before inclusion
- •4. Current diagnosis of neurological disorders
- •5. Cognitive dysfunction
- •6. Severe or uncontrolled organic disease, likely to interfere with the conduct of the study
研究者
相似试验
已完成
3 期
Efficacy and safety of agomelatine for 12 weeks in non-depressed out-patients with Generalised Anxiety DisorderGeneralised Anxiety DisorderMental and Behavioural DisordersOther anxiety disordersISRCTN03554974Institut de Recherches Internationales Servier (France)390
已完成
3 期
Efficacy of agomelatine given orally on rest/activity circadian rhythms in outpatients with major depressive disorder: a randomised, double-blind international study with parallel groups versus Selective Serotonin Reuptake Inhibitor (SSRI). Six-week treatment plus optional continuation for 18 weeks.Major depressive disorderMental and Behavioural DisordersDepressionISRCTN49376288Institut de Recherches Internationales Servier (France)300
已完成
3 期
Efficacy and safety of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally for eight weeks in out-patients with severe major depressive disorder: a randomised double-blind, parallel groups, international study versus selective serotonin reuptake inhibitor (SSRI) with a double-blind extension period of 16 weeksMajor depressive disorderMental and Behavioural DisordersDepressive episodeISRCTN19313268Institut de Recherches Internationales Servier (France)500
进行中（未招募）
不适用
Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of treatment) given orally during 16 weeks in patients with Obsessive-Compulsive Disorder. A randomised, double-blind, placebo-controlled, parallel groups, international study. - NDMedDRA version: 12.1Level: LLTClassification code 10029898Term: Obsessive-compulsive disorderObsessive-compulsive disorderEUCTR2009-016713-20-ITINSTITUT DE RECHERCHES INTERNATIONALES SERVIER80
尚未招募
2 期
Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of treatment) given orally during 16 weeks in patients with Obsessive-Compulsive Disorder.A randomised, double-blind, placebo-controlled, parallel groups, international study.psychiatrische en obsessieve en compulsieve stoornissenObsessive Compulsive DisorderNL-OMON34855Servier R&D Benelux15